CHINA REIMBURSEMENT LIST

Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list

The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people.